Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial

Maitland, ML; Piha-Paul, S; Falchook, G; Kurzrock, R; Nguyen, L; Janisch, L; Karovic, S; McKee, M; Hoening, E; Wong, S; Munasinghe, W; Palma, J; Donawho, C; Lian, GK; Ansell, P; Ratain, MJ; Hong, D

Maitland, ML (reprint author), Univ Chicago, Dept Med, Hematol Oncol Sect, 5841 S Maryland Ave, Chicago, IL 60637 USA.; Maitland, ML (reprint author), Univ Chicago, Comm Clin Pharmacol & Pharmacogen, 5841 S Maryland Ave, Chicago, IL 60637 USA.; Maitland,

BRITISH JOURNAL OF CANCER, 2018; 118 (8): 1042

Abstract

BACKGROUND: Ilorasertib (ABT-348) inhibits Aurora and VEGF receptor (VEGFR) kinases. Patients with advanced solid tumours participated in a phase 1 do......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索